·þÎñÈÈÏß
×ð³Á¿Æѧ ¾´Î·Ôì¶È ×êӪЧÄÜ ¹Ø°®ÐÔÃü
ѧÊõ¶¯Ì¬
×ðÁú¼¯ÍŹÙÍø¹¹½¨LOXO-292ÄÍÒ©Ë«Í»±ä¹¤³Ìϸ°ûÖêÖúÁ¦RETÒÖÔì¼Á¿ª·¢
°ä²¼¹¦·ò£º
2021-06-22
RET£¨Rearranged during transfection£©»ùÒòÓÚ1985Äê³õ´ÎÔÚÈËTÁÜ°ÍÁöϸ°ûÖз¢ÏÖ£¬ÇÒ±»¼ø¶¨ÎªÒ»¸öÔ°©»ùÒò£¬RET»ùÒòλÓÚÈËÀà10ºÅ³£È¾É«Ì峤±Û£¨10q11.2£©£¬±àÂëÒ»ÖÖ´æÔÚÓÚϸ°ûĤÉϵÄÊÜÌåÀÒ°±Ëἤø£¨RTK£©[1] ¡£RETµ°°×ÔÚ³ÉÊì¹ý³ÌÖУ¬µ°°×Ç°Ìåͨ¹ý·ÖÆçµÄÑ¡ÔñÐÔ¼ôÇз½Ê½£¬ÖØÒªÐγÉÁ½ÖÖµ°°×ÑÇÐÍRET-9ºÍRET-51 ¡£RET¼¤Ã¸±»Éñ¾½ºÖÊϸ°ûÏ·´Ô´µÄÉñ¾ÓªÑø³É³¤Òò×ÓGDNF¼¤»î£¬GFNFÓëGFRα1½áºÏÐγÉGDNF-GFRα1¸´ºÏÎ´Ë¸´ºÏÎïÔÙÓëRET½áºÏÐγÉÈý¸´ºÏÌ壬ÒýÆðRETµÄ¶þ¾Û»¯£¬²¢ÒýÆðÀÒ°±Ëá²Ð»ù×ÔÁ×Ëữ£¬´Ó¶ø¼¤»îÏÂÓÎÐźÅͨ·[2]£¬Ô̺¬RAS/MARK¡¢PI3K/AKT¡¢PLCγ/PKCµÈÐźÅͨ·£¬½ø¶øÒýÆðϸ°ûµÄÔöÖ³·Ö»¯¡¢Ç¨áã¡¢ÔÙÉúºÍ³É³¤µÈ[1] ¡£
ͼ1. a) RET¼¤Ã¸½á¹¹;b) RET¼¤Ã¸»î»¯»úÔì¼°ÐźÅͨ· ¡£
(ͼƬÆðÔ´Óڲο¼×ÊÁÏ[2])
RET»ùÒòÖ°©»úÔ죬ÖØÒªÓлùÒòÈںϡ¢µãÍ»±ä¡¢»ùÒòÀ©ÔöºÍȾɫÌå³ÁÅŵÈ[3] ¡£È¾É«ÌåµÄ³Á×é³ £»áµ¼ÖÂRET»ùÒòÖÐÑë¶ÏÁѺóÓë·ÖÆçµÄÉÏÓλùÒò²úÉúÈںϣ¬½ø¶øÐγÉÇý¶¯Ö×Áöϸ°ûÔöÖ³µÄÈںϻùÒò ¡£ÔÚ1990ÄêºÍ2012ÄêÏȺóÔÚ¼××´ÏÙÈéÍ·×´°©¡¢·ÎÏÙ°©ºÍÂýÐÔËèϵ°×Ѫ²¡Öз¢ÏÖÕâÒ»±äÒì ¡£ÆäÖÐÈںϻùÒòÖØÒªÓУºKIF5B-RET£¨×î¶à£©£¬CCDC6-RETºÍNCOA4-RET £»RET»ùÒòÔÚNSCLC»¼ÕßÖØÒªÒÔRET»ùÒòÈںϴó¾Ö²úÉúŤת£¬×êÑÐÏÔʾ·ÇÓ×ϸ°û·Î°©ÖÐKIF5B©\RETÈÚºÏÔ¼Õ¼ËùÓÐRETÈÚºÏµÄ 68.3 %£¬Æä´ÎΪCCDC6©\RET (16.8 %)¼°NCOA4©\RET (1.2 %)[4] ¡£¹ÌÈ»RET»ùÒòÔÚNSCLC»¼ÕßÖеķ¢²¡ÂʽöΪ1.4 %-2.5 %£¬µ«ÊÇÎÒ¹úµÄ»¼Õß»ùÊý¼«¶È´ó£¬Òò¶øЯ´øRET»ùÒòÈںϵÄNSCLC»¼Õß²¢²»ÉÙ¼û[5] ¡£µãÍ»±ä¶àλÓÚGate keeper²Ð»ù£¬ÖØÒªÊÇV804λµã£¨V804M£¬V804L£©£¬»¹Ô̺¬ÈܼÁÇ°ÑØÍ»±äG810λµã£¨G810R£¬G810S£¬G810C£¬G810A£¬G810V£©¡¢M918TºÍC634λµã£¨C634R£¬C634G£¬C634F£¬C634S£¬C634W£¬C634Y£¬C634K£©Í»±äµÈ[1] ¡£
ͼ2. ·ÖÆç°©Ö¢ÖÐRET»ùÒòŤתµÄ¸ÅÊö ¡£
(ͼƬÆðÔ´Óڲο¼×ÊÁÏ[3])
ͼ3. RET»ùÒòµÄÖØÒªÈںϷ½Ê½ºÍµãÍ»±äλµã ¡£
(ͼƬÆðÔ´Óڲο¼×ÊÁÏ[1])
2011ÄêºÍ2013Ä꣬FDAºÍEMA±ðÀëºË×¼VandetanibºÍCabozantinibÓÃÓÚÒ½ÖνøÕ¹µÄÍíÆÚµÄMTC»¼Õߣ¬²¢ÒÑÔÚRETÈÚºÏÑôÐÔNSCLC»¼ÕßÖÐÏÔʾ³ö»îÐÔ[1] ¡£µ«ÉÏÊöÒ©ÎïÕûÌå¶ÔÓÚRET»ùÒòÈÚºÏÍ»±äµÄ°ÐÏòÌØÒìÐÔ²¢²»Ç¿£¬Æä²»½öÒÖÔìRETµ°°×Ðźţ¬Í¬Ê±»áÒÖÔìVEGFR¡¢EGFRµÈÆäËûµ°°×£¬ÓÐЧÐÔÏà¶Ô½Ï²î£¬ÇÒ¸±×÷ÓúͷǰÐÏò¶¾ÐÔÔö³¤ ¡£2020Äê5ÔÂ9ÈÕ£¬FDA¼Ó¿ìºË×¼ÁËLoxo Oncology¹«Ë¾(ÀñÀ´ÆìÏÂ)selpercatinib(LOXO-292£¬Retevmo)ÉÏÊУ¬ÓÃÓÚÒ½Öβ¿ÃÅRETÈںϻùÒòµÄ·ÇÓ×ϸ°û·Î°©³ÉÈË»¼Õߣ¬ºÍÍíÆÚRETÍ»±äÑôÐÔ¼××´ÏÙËèÑù°©(MTC)»¼Õß¼°ÍíÆÚ»òתÒƵÄRETÈÚºÏÑôÐÔ¼××´ÏÙ°©»¼Õß ¡£ÕâÊÇFDAºË×¼µÄÊ׿î¸ßÑ¡ÔñÐÔRET¼¤Ã¸ÒÖÔì¼Á ¡£Selpercatinib(LOXO-292)ÊÇ¿Ú·þÓÃÒ©µÄATP¾ºÕùÐÔÓ×·Ö×ÓRET¼¤Ã¸ÒÖÔì¼Á£¬ËüÓµÓд©Í¸ÖÐÊàÉñ¾ÏµÍ³(CNS)µÄÄÜÁ¦£¬²¢ÇÒÄܹ»°ÐÏò¼¤»îÐÔRETÈںϡ¢µãÍ»±äºÍijЩ»ñµÃÐÔÄÍÒ©Í»±ä(¶ÔÔ̺¬KIF5B-RETºÍCCDC6-RETÈÚºÏÀàÐÍ£¬ÒÔ¼°RET-V804L/MºÍM918TÄÍÒ©Í»±äÃô¸Ð)[1] ¡£2020Äê9ÔÂ5ÈÕ£¬FDAºË×¼À¶Í¼¹«Ë¾(Blueprint Medicines Corporation)¿ª·¢µÄRETÒÖÔì¼ÁPralsetinib(BLU-667£¬Gavreto)ÉÏÊУ¬ÓÃÓÚÒ½ÖÎRETÈÚºÏÑôÐÔתÒÆÐÔ·ÇÓ×ϸ°û·Î°©(NSCLC)³ÉÈË»¼Õß[1] ¡£2021Äê3ÔÂ24ÈÕ£¬BLU667(ÆÕÀÌæÄá, ÉÌÆ·Ãû£ºÆÕ¼ª»ª®)»ñµÃÖйú¹ú¶ÈÒ©Æ·¼à¶½ÖÎÀí¾Ö(NMPA)ºË×¼£¬ÓÃÓÚ¼ÈÍù½ÓÊܹýº¬²¬»¯ÁƵÄRET»ùÒòÈÚºÏÑôÐԵIJ¿ÃÅÍíÆÚ»òתÒÆÐÔNSCLC³ÉÈË»¼Õߣ¬³ÉΪ¹úÄÚÊ׸öÒ²ÊÇĿǰΨһ»ñÅúµÄRETÒÖÔì¼Á[1] ¡£
²»Í⣬ÈçͬÆäËû°ÐÏòÒ©Ò»Ñù£¬ÄÍÒ©ÊDz»³ÉÔ¤·ÀµÄ ¡£2020Äê1ÔÂ24ÈÕ£¬¡¶J Thorac Oncol¡·±¨Â·ÁË2ÀýRETÈںϷÇÓ×ϸ°û·Î°©»¼ÕßÔÚʹÓÃLOXO-292ºó³öÏÖÈܼÁÇ°ÑØÍ»±ä(RET G810R/S/C)£¬½ø¶øµ¼ÖÂLOXO-292ÄÍÒ© ¡£½á¹¹Ä£ÐÍÔ¤²â£¬RETÈܼÁÇ°ÑØÍ»±äG810R/S/C/VÍ»±äÔÚ¿Õ¼äÉϹÊÕÏÁËSelpercatinibµÄ½áºÏ£¬Ìå±íÊÔÑé֤ʵ¿¹RET¶à¼¤Ã¸ÒÖÔì¼ÁMKIºÍÑ¡ÔñÐÔRET TKIs¾ùʧȥ»îÐÔ£¬Pralsetinib(BLU-667)¶ÔG810SÃô¸Ð[6] ¡£2021Äê4ÔÂ10ºÅ£¬Loxo Oncology¹«Ë¾±¨Â·£¬ÔÚ»¼ÕßÖгöÏÖRETÈܼÁÇ°ÑØÍ»±äG810λµãºÍÃÅ¿ØÍ»±äV804λµãµÄË«Í»±ä£¬¼°M918TλµãºÍÈܼÁÇ°ÑØÍ»±äG810λµãµÄË«Í»±ä ¡£Ìå±í³¢ÊÔÁ˾ÖÏÔʾ£¬RET²úÉúË«Í»±äºó£¬¶ÔSelpercatinib(LOXO-292)ºÍPralsetinib(BLU-667)ÒÖÔì¼Á²»Ãô¸Ð[7] ¡£
ͼ4. Ñ¡ÔñÐÔRETÒÖÔì¼ÁÄÍÒ©ÐԵķÂÕÕ ¡£
(ͼƬÆðÔ´Óڲο¼×ÊÁÏ[6])
Õë¶ÔRET¼¤Ã¸ÒÖÔì¼ÁÒ©Î￪·¢ºÍÐèÒª£¬×ðÁú¼¯ÍŹÙÍø¹¹½¨Ò»ÏµÁÐBa/F3-RETË«Í»±äµÄ¹¤³Ìϸ°ûÖ꣬ÓÃÓÚÕë¶ÔRET°ÐµãµÄ»¯ºÏÎïɸÐò¼°¶¯ÎïҩЧÆÀ¼Û£¬Ó½Ó¿í´ó¿Í»§Õ÷ѯºÏ×÷ ¡£
ϸ°ûÖêÁбí
²¿ÃÅϸ°ûÖêÌå±íÑéÖ¤Êý¾Ý
²¿ÃÅϸ°ûÖêÌåÄÚÄ£ÐÍÑéÖ¤Êý¾Ý
BLU-667 in Ba/F3-KIF5B-RET Model
BLU-667¡¢LOXO-292 in Ba/F3-KIF5B-RET-V804M Model
BLU-667¡¢LOXO-292 in Ba/F3-KIF5B-RET-V804L Model
BLU-667¡¢LOXO-292 in Ba/F3-KIF5B-RET-G810C Model
BLU-667¡¢LOXO-292 in Ba/F3-KIF5B-RET-G810R Model
BLU-667¡¢LOXO-292 in Ba/F3-KIF5B-RET-G810S Model
²¿ÃÅCDXÄ£ÐÍÑéÖ¤Êý¾Ý
LOXO-292 in LC-2/ad Model
LOXO-292 in TT Model
²Î¿¼Îļþ¼°Í¼Æ¬ÆðÔ´£º
1. The importance of the RET gene in thyroid cancer and therapeutic implications. Nature, 2021 May,17:296–306.
2. To Bud or not to Bud: The RET perspective in CAKUT. Pediatr Nephrol. 2014 Apr; 29(4): 597–608.
3. RET Aberrations in Diverse Cancers. Clin Cancer Res; 23(8) April 15, 2017,1988-1997.
4. Curigliano G, et al. 2021 ASCO, Poster 9089.
5.Öйú·ÇÓ×ϸ°û·Î°© RET »ùÒòÈÚºÏÁÙ´²¼ì²âר¼Ò¹²Ê¶. Öлª²¡ÀíѧÔÓÖ¾, 2021, 50(6): 583-591.
6. RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies. Journal of Thoracic Oncology Vol. 2020.15 No. 4: 541-549.
7. Pre-clinical characterization of potent and selective next-generation RET inhibitors. Loxo Oncology at Lilly. Presented at: AACR Annual Meeting 2021.
×ðÁú¼¯ÍŹÙÍø¹«¼ÒºÅ
´´ÐÂÒ©ÎïÆÀ¼Û
ÖпÆÒ½ÂöÓ×·¨Ê½
µç»°£º4006 0551 06£¨¹Ù·½ÈÈÏߣ©
0551—67129201£¨¹«Ë¾×ܲ¿£©
꿅᣼www.precedo.cn
µØÖ·£ººÏ·ÊÊиßÐÂÇøÏ°ÓÑ·¹ú¶È½¡È«´óÊý¾Ý²úÒµÔ°A6¶°
Copyright © 2021 ×ðÁú¼¯ÍŹÙÍø °æȨËùÓÐ | SEO±êÇ©
ÍøÕ¾½¨É裺ÖÐÆó¶¯Á¦ ºÏ·Ê